Top

EJNMMI Research

Published in:

01-12-2020 | Computed Tomography | Original research

RETRACTED ARTICLE: Inter- and intraobserver agreement of the quantitative assessment of [^99mTc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer

Authors: Daniel Johnathan Hughes, Gitasha Chand, Vicky Goh, Gary J. R. Cook

Published in: EJNMMI Research | Issue 1/2020

Abstract

Purpose

Checkpoint inhibition therapy using monoclonal antibodies against programmed cell death protein 1 (PD-1) or its ligand (PD-L1) is now standard management of non-small cell lung cancer (NSCLC). PD-L1 expression is a validated and approved prognostic and predictive biomarker for anti-PD-1/PD-L1 therapy. Technetium-99 m [^99mTc]-labelled anti-PD-L1 single-domain antibody (NM-01) SPECT/CT quantification correlates with PD-L1 expression in NSCLC, presenting an opportunity for non-invasive assessment. The aim of this study was to determine the inter- and intraobserver agreement of the quantitative assessment of [^99mTc]NM-01 SPECT/CT in NSCLC.

Methods

[^99mTc]NM-01 SPECT/CT studies of 21 consecutive NSCLC participants imaged for the evaluation of PD-L1 expression were analysed. Three independent observers measured maximum counts in a tumour region of interest (ROI_max) of primary lung, metastatic lesions and normal tissue references of both 1 and 2 h post-injection (n = 42) anonymised studies using a manual technique. Intraclass correlation coefficients (ICC) were calculated, and Bland–Altman plot analysis was performed to determine inter- and intraobserver agreement.

Results

Intraclass correlation of primary lung tumour-to-blood pool (T:BP; ICC 0.83, 95% CI 0.73–0.90) and lymph node metastasis-to-blood pool (LN:BP; ICC 0.87, 0.81–0.92) measures of [^99mTc]NM-01 uptake was good to excellent between observers. Freehand ROI_max of T (ICC 0.94), LN (ICC 0.97), liver (ICC 0.97) and BP (ICC 0.90) reference tissues also demonstrated excellent interobserver agreement. ROI_max scoring of healthy lung demonstrated moderate to excellent interobserver agreement (ICC 0.84) and improved when measured consistently at the level of the aortic arch (ICC 0.89). Manual ROI_max re-scoring of T, LN, T:BP and LN:BP using [^99mTc]NM-01 SPECT/CT following a 42-day interval was consistent with excellent intraobserver agreement (ICC range 0.95–0.97).

Conclusion

Good to excellent inter- and intraobserver agreement of the quantitative assessment of [^99mTc]NM-01 SPECT/CT in NSCLC was demonstrated in this study, including T:BP which has been shown to correlate with PD-L1 status. [^99mTc]NM-01 SPECT/CT has the potential to reliably and non-invasively assess PD-L1 expression.

Clinical trial registration

ClinicalTrials.gov identifier no. NCT02978196. Registered 30th November 2016.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Yuan M, Huang L-L, Chen J-H, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Therapy. 2019;4(1):10. https://doi.org/10.1038/s41392-019-0099-9.CrossRef

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Updated Analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537–46. https://doi.org/10.1200/jco.18.00149.CrossRefPubMed

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, Von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65. https://doi.org/10.1016/s0140-6736(16)32517-x.CrossRefPubMed

Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018;29(4):959–65. https://doi.org/10.1093/annonc/mdy041.CrossRefPubMed

Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46. https://doi.org/10.1016/s0140-6736(16)00587-0.CrossRefPubMed

Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50. https://doi.org/10.1016/S0140-6736(15)01281-7.CrossRefPubMed

McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, et al. Quantitative assessment of the heterogeneity of pd-l1 expression in non-small-cell lung cancer. JAMA Oncol. 2016;2(1):46–54. https://doi.org/10.1001/jamaoncol.2015.3638.CrossRefPubMedPubMedCentral

Kim T-J, Hong SA, Kim O, Kim SJ, Yang J-H, Joung EK, et al. Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer. Oncotarget. 2017. https://doi.org/10.18632/oncotarget.22582.CrossRefPubMedPubMedCentral

10.

Udall M, Rizzo M, Kenny J, Doherty J, Dahm S, Robbins P, et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagn Pathol. 2018. https://doi.org/10.1186/s13000-018-0689-9.CrossRefPubMedPubMedCentral

11.

Xing Y, Chand G, Liu C, Cook GJR, O’Doherty J, Zhao L, et al. Early phase I study of a 99mTc-Labeled anti-programmed death ligand-1 (PD-L1) single-domain antibody in SPECT/CT assessment of PD-L1 expression in non-small cell lung cancer. J Nucl Med. 2019;60(9):1213–20. https://doi.org/10.2967/jnumed.118.224170.CrossRefPubMedPubMedCentral

12.

Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15(2):155–63. https://doi.org/10.1016/j.jcm.2016.02.012.CrossRefPubMedPubMedCentral

13.

Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, Van Dongen GAMS, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun. 2018. https://doi.org/10.1038/s41467-018-07131-y.CrossRefPubMedPubMedCentral

14.

Dickson J, Ross J, Vöö S. Quantitative SPECT: the time is now. EJNMMI Phys. 2019. https://doi.org/10.1186/s40658-019-0241-3.CrossRefPubMedPubMedCentral

Title: RETRACTED ARTICLE: Inter- and intraobserver agreement of the quantitative assessment of [99mTc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer
Authors: Daniel Johnathan Hughes
Gitasha Chand
Vicky Goh
Gary J. R. Cook
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Keywords: Computed Tomography
NSCLC
Computed Tomography
NSCLC
Published in: EJNMMI Research / Issue 1/2020
Electronic ISSN: 2191-219X
DOI: https://doi.org/10.1186/s13550-020-00734-x

At a glance: The STEP trials

Springer Medicine

RETRACTED ARTICLE: Inter- and intraobserver agreement of the quantitative assessment of [^99mTc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer

Abstract

Purpose

Methods

Results

Conclusion

Clinical trial registration

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Clinical trial registration

Please log in to get access to this content

Other articles of this Issue 1/2020

The feasibility of [18F]EF5-PET/CT to image hypoxia in ovarian tumors: a clinical study

Correction to: Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT

Radiobiological and dosimetric assessment of DNA-intercalated 99mTc-complexes bearing acridine orange derivatives

Impact of the Q.Clear reconstruction algorithm on the interpretation of PET/CT images in patients with lymphoma

Interobserver agreement of [68Ga]Ga-PSMA-11 PET/CT images interpretation in men with newly diagnosed prostate cancer

TSPO PET detects acute neuroinflammation but not diffuse chronically activated MHCII microglia in the rat